# Pizarra — PT-pseudo_3cc88c81f35a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3cc88c81f35a
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.206 ng/mL²
  - PSA velocity: 0.78 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 40.2 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69907415 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 2. PSAD 0.21. Prostate volume 40 mL. DRE nodus. csPCa 0.70.

Vitals: weight 85 kg, height 180 cm, BMI 26.2, BP 114/76 mmHg, HR 88 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2010).

Chief complaint: Clinical review sought after a previous prostate biopsy and a recent PSA increase to 8.3 ng/mL.

History: He is a 66-year-old man initially flagged for an elevated PSA during routine primary care screening in 2023. Subsequent monitoring involved serial blood work and a previous biopsy that returned Positive for low-grade disease. He works as a retired warehouse worker, remains married, and shares a multi-generational household with his spouse and an adult child. Daily life revolves around gardening rather than formal exercise. He is an Ex-smoker (11 pack-yr, quit 2010), while alcohol intake remains minimal at roughly one unit weekly. He experiences occasional mild urinary hesitancy and nocturia, corresponding to an IPSS score of 17, yet explicitly denies bone pain, unexplained weight loss, or haematuria. Comorbidities: none. Active medication: None.

Physical examination: DRE: firm, asymmetrically enlarged prostate with a discrete Nodus palpable in the left peripheral zone. The rest of the abdominal and cardiovascular evaluation remains unremarkable, documenting a blood pressure of 114/76 mmHg and a steady heart rate of 88 bpm. Overall, he presents as well-appearing without pallor or peripheral lymphadenopathy.

Patient info: retired warehouse worker; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Gardening, no structured exercise; IPSS score: 17/35 (moderate LUTS).


Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.22   (95% CI 0.06-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.20  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 3.1 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=3.0, psa=8.3, age=66.0, psad=0.206, dre_ord=1.0, vol=40.2, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.78 ng/mL/yr) against the PI-RADS 2 score, which is a key factor in risk stratification. It also could not incorporate the history of a prior positive biopsy, which significantly alters the interpretation of the current findings. Finally, it did not see the full context of the laboratory panel or the mpMRI report, which are crucial for assessing the actual extent of the lesion suggested by the PI-RADS 2 score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.43 +/- 0.22), indicating high uncertainty. A failure mode is the contradiction between the low PI-RADS score (2) and the rising PSA (from 6.7 to 8.3 ng/mL) and the elevated PSA velocity (0.78 ng/mL/yr). Another failure mode is ignoring the prior positive biopsy result; if the prior positive result indicates a high likelihood of clinically significant cancer, the current low PI-RADS score might be misleading. The 'discuss' tier suggests the panel is insufficient to resolve the conflict between the low imaging score and the rising biochemical markers.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details high-risk features despite PI-RADS 2, it would increase the likelihood of biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the likelihood of biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain clinical context regarding the prior positive biopsy result or LUTS severity.
  <document> laboratory results (full panel) -> This panel might contain other markers (e.g., PSA density context) that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Subject: Multiparametric MRI of the Prostate | Ziekenhuis Gelderse Vallei, Ede | 24 January 2025

  Clinical indication: Re-evaluation for rising PSA (8.3 ng/mL) and prior positive biopsy.

  FINDINGS: The gland measures 40.2 mL in total volume, appearing homogeneous on T2-weighted imaging with mild transition zone enlargement. A roughly 6 mm well-defined nodule with benign characteristics occupies the anterior transition zone apex. The peripheral zone lacks any focal T2-hypointense lesions. Symmetric diffusion is observed on DWI, showing no restricted uptake, while dynamic contrast enhancement remains negative for early focal signals. There is no evidence of extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy.

  IMPRESSION: PI-RADS 2. Prostate volume 40.2, PSA density 0.206. No PI-RADS 3+ lesion identified. csPCa predicted probability 0.69907415.

  **PSA history**
  {"case_id": "PT-pseudo_3cc88c81f35a", "psa_trend": [{"date": "May 2023", "val": 2.5}, {"date": "Dec 2023", "val": 4.2}, {"date": "Jul 2024", "val": 7.2}, {"date": "Jan 2025", "val": 8.3}]}

  **previous GP / urology consultation notes**
  {"date": "01 Jun 2024", "author": "Dr. M. Jansen (GP)", "text": "Serial screening detected a PSA value of 6.7 ng/mL, marking a modest rise from the preceding 6.4 ng/mL measurement. Aside from occasional mild urinary frequency, he experiences no lower urinary tract symptoms. A follow-up blood draw was planned for late summer to track the trend prior to any specialist involvement."}, {"date": "29 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "Clinical review focused on the persistent PSA elevation. Latest labs indicate a further climb to 8.3 ng/mL alongside a %free PSA reading of 18%. Consequently, a urology outpatient appointment was booked for comprehensive assessment, and prior scan and biopsy records were requested for the visit."}

  **laboratory results**
  {"name": "PSA", "val": "8.3 ng/mL", "date": "24 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.48 ng/mL", "date": "24 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "18%", "date": "24 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "16.5 g/dL", "date": "24 Dec 2024", "flag": ""}, {"name": "WBC", "val": "3.0 x10^9/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "255 x10^9/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "89 umol/L", "date": "24 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "24 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "16.7 nmol/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "93 U/L", "date": "24 Dec 2024", "flag": ""}, {"name": "LDH", "val": "166 U/L", "date": "24 Dec 2024", "flag": ""}}

NOT RETRIEVED
  get_family_history - Do NOT call this. In this reading form the family-history anamnesis is not part of the biopsy work-up, and a positive or negative first-degree history does not change whether this patient is sampled today.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PSA velocity: 0.78 ng/mL/yr (rapid rise).
  Prior positive biopsy: Positive (suggests prior clinically significant disease).
  PSA trend: Rising from 6.7 ng/mL to 8.3 ng/mL over the monitoring period.

  AGAINST sampling this patient now:
  mpMRI PI-RADS score: 2 (low risk).
  mpMRI finding: No PI-RADS 3+ lesion identified.

WHERE THIS LEANS
  The evidence is conflicted: biochemical markers (rising PSA velocity and prior positive biopsy) suggest a need for further investigation, while the imaging (PI-RADS 2) suggests low risk. This contradicts the statistical prior of 'NO BIOPSY' by highlighting concerning biochemical trends that the prior ignored.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

A biopsy is recommended because the biochemical evidence strongly suggests progression despite a low imaging score. The patient has a rising PSA velocity of 0.78 ng/mL/yr and a prior positive biopsy, which are significant factors. Although the PI-RADS score is 2, the rising PSA from 6.7 ng/mL to 8.3 ng/mL, coupled with the prior positive result, warrants further investigation to rule out clinically significant disease.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
